CaltechAUTHORS
  A Caltech Library Service

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

Balazs, Alejandro B. and Ouyang, Yong and Hong, Christin M. and Chen, Joyce and Nguyen, Steven M. and Rao, Dinesh S. and An, Dong Sung and Baltimore, David (2014) Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nature Medicine, 20 (3). pp. 296-300. ISSN 1078-8956 . http://resolver.caltech.edu/CaltechAUTHORS:20140218-133808799

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:20140218-133808799

Abstract

The vast majority of new HIV infections result from relatively inefficient transmission of the virus across mucosal surfaces during sexual intercourse. A consequence of this inefficiency is that small numbers of transmitted founder viruses initiate most heterosexual infections. This natural bottleneck to transmission has stimulated efforts to develop interventions that are aimed at blocking this step of the infection process. Despite the promise of this strategy, clinical trials of preexposure prophylaxis have had limited degrees of success in humans, in part because of lack of adherence to the recommended preexposure treatment regimens. In contrast, a number of existing vaccines elicit systemic immunity that protects against mucosal infections, such as the vaccines for influenza and human papilloma virus. We recently demonstrated the ability of vectored immunoprophylaxis (VIP) to prevent intravenous transmission of HIV in humanized mice using broadly neutralizing antibodies. Here we demonstrate that VIP is capable of protecting humanized mice from intravenous as well as vaginal challenge with diverse HIV strains despite repeated exposures. Moreover, animals receiving VIP that expresses a modified VRC07 antibody were completely resistant to repetitive intravaginal challenge by a heterosexually transmitted founder HIV strain, suggesting that VIP may be effective in preventing vaginal transmission of HIV between humans.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.1038/nm.3471DOIArticle
http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3471.htmlPublisherArticle
http://www.nature.com/nm/journal/v20/n3/extref/nm.3471-S1.pdfPublisherSupplementary material
Additional Information:© 2014 Macmillan Publishers Limited. Received 3 October 2013; accepted 7 January 2014; published online 9 February 2014. We acknowledge G. Nabel (Sanofi-Pasteur) and J. Mascola (US National Institutes of Health (NIH) Vaccine Research Center) for VRC01, VRC-PG04, VRC07 and VRC07G54W expression plasmids and proteins, D. Burton (Scripps) for b12, PG9, PGT121 and PGT128 expression plasmids, M. Nussenzweig (Rockefeller) for 3BNC117 and 12A12 expression plasmids and P. Bjorkman (California Institute of Technology) for the NIH45-46W expression plasmid. We also thank the Caltech Protein Expression Center for providing purified antibodies. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH: pYK-JRCSF from I.S.Y. Chen and Y. Koyanagi, pREJO.c/2864 from J. Kappes and C. Ochsenbauer and TZM-bl cells from J. Kappes and X. Wu. We thank J. Kim, D. Majumdar, M. Mann and A. So for their helpful comments and other members of the Baltimore lab, as well as R. Cortado and S. Shimizu in the An lab, for their assistance in carrying out this work. Preparation of human CD34+ cells, tissue procurement and BLT mice were supported by the UCLA Center for AIDS Research (CFAR) AI028697. A.B.B. is supported by the NIAID Career Transition Award 1K22AI102769. D.S.R. was a Sidney Kimmel Scholar supported by the Sidney Kimmel Foundation for Cancer Research (Translational Award SKF-11-013) and is supported by career development award 1K08CA133521 from the NIH. D.S.A. is supported by NIAID grant 1R01AI100652-01A1. This project was supported by the NIH (HHSN266200500035C) through a contract from the NIAID and by the Joint Center for Translational Medicine. Author Contributions: A.B.B. and D.B. conceived the study. A.B.B. designed the experiments. D.S.A. offered suggestions for the experiments and provided the BLT humanized mice. A.B.B., Y.O., C.M.H., J.C. and S.M.N. carried out experiments. A.B.B., Y.O., C.M.H., J.C. and S.M.N. analyzed the data. D.S.R. performed immunohistochemistry and analysis. A.B.B. and D.B. wrote the paper with contributions from all authors.
Funders:
Funding AgencyGrant Number
UCLA Center for AIDS Research (CFAR)AI028697
NIAID Career Transition Award1K22AI102769
Sidney Kimmel Foundation for Cancer ResearchSKF-11-013
NIH1K08CA133521
NIAID1R01AI100652-01A1
NIHHHSN266200500035C
Joint Center for Translational MedicineUNSPECIFIED
Record Number:CaltechAUTHORS:20140218-133808799
Persistent URL:http://resolver.caltech.edu/CaltechAUTHORS:20140218-133808799
Official Citation:Balazs, A. B., Ouyang, Y., Hong, C. M., Chen, J., Nguyen, S. M., Rao, D. S., . . . Baltimore, D. (2014). Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. [Letter]. Nat Med, 20(3), 296-300. doi: 10.1038/nm.3471
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:43853
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:18 Feb 2014 22:09
Last Modified:11 Apr 2014 16:49

Repository Staff Only: item control page